• Politics
  • Diversity, equity and inclusion
  • Financial Decision Making
  • Telehealth
  • Patient Experience
  • Leadership
  • Point of Care Tools
  • Product Solutions
  • Management
  • Technology
  • Healthcare Transformation
  • Data + Technology
  • Safer Hospitals
  • Business
  • Providers in Practice
  • Mergers and Acquisitions
  • AI & Data Analytics
  • Cybersecurity
  • Interoperability & EHRs
  • Medical Devices
  • Pop Health Tech
  • Precision Medicine
  • Virtual Care
  • Health equity

Health Tech Partnership Promotes AI-Driven Drug Discovery


The partnership will give clients increased efficiency and diversity in the drug discovery process.

drug discovery, AI, artificial intelligence, big data

A new partnership announced today between Charles River Laboratories and Atomwise will offer biotech and pharmaceutical companies an end-to-end discovery solution that brings together artificial intelligence (AI) technology with premium research services.

Charles River provides products and services to help companies accelerate their research and drug development. The partnership will give its clients access to Atomwise’s AI-powered, structure-based, drug design technology that allows scientists to predict how well a small molecule will bind to a target protein of interest.

>> READ: Will AI Replace the Radiologist?

Atomwise’s technology analyzes billions of compounds and screens challenging target proteins in the small molecule drug discovery process. The AI allows researchers to quickly test a large and diverse chemical space and only focuses on compounds predicted to have improved target-binding attributes.

The partnership will give Charles River’s clients increased efficiency and diversity in the drug discovery process.

“By cutting time out of each stage of the drug discovery process, we enable our clients to deliver novel therapeutics to patients more efficiently and effectively,” said James Foster, president and CEO of Charles River.

Atomwise will support hit discovery, hit-to-lead and lead optimization efforts and will receive technology access fees, milestone-based payments and royalties from clients — a value the company projects could exceed $2.4 billion.

“Through this collaboration, we will bring our technology and experience in drug discovery to more biotech and pharma partners, furthering our mission to discover and develop new medicines for patients,” said Atomwise CEO Abraham Heifets, Ph.D.

Get the best insights in healthcare analytics directly to your inbox.


High-Tech Drug Discovery Startup Kallyope Bags $21M in Funding

How AI Is Shaking Up Healthcare, Beyond Diagnostics

FDA Unveils MyStudies App with Aim to Collect Real-World Data

Related Videos
Image: Ron Southwick, Chief Healthcare Executive
George Van Antwerp, MBA
Edmondo Robinson, MD
Craig Newman
Related Content
© 2024 MJH Life Sciences

All rights reserved.